GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

11

Streptococcus anginosus–Derived Methionine Promotes Gastric Cancer Progression: Gut | July 2026

Introduction: Streptococcus anginosus has emerged as a microbial signature associated with gastric cancer, but the mechanism linking this bacterium to tumour progression has remained unclear. This study identifies...

12

GSK3βhigh/NFATc1high in Treatment of Pancreatic Cancer: Gut | July 2026

Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-resistant cancers, with rapid recurrence and poor survival despite surgery and chemotherapy. This study identifies a novel molecular...

13

VIDA mRNA: Cell | July 2026

Introduction: Current antiviral therapies are generally virus-specific and vulnerable to viral mutations. Inspired by the success of mRNA vaccines, this study introduces Viral Protease-Initiated Lytic Cell Death (VIDA)—a...

14

A20 Protects Against Autoimmune Hepatitis: Gut | July 2026

The July 2026 Gut study on “A20 Protects Against Autoimmune Hepatitis” shows that A20 is a critical protective factor in autoimmune hepatitis (AIH) and helps prevent liver damage...

15

KLF9 Links Intermittent Hypoxia to MASLD: Hepatology | July 2026

Introduction: Obstructive sleep apnea (OSA) is increasingly recognized as an important metabolic risk factor due to recurrent episodes of intermittent hypoxia (IH). Clinical studies have linked OSA with...

16

Catestatin Improves Glucose Control by Modulating Gut Motility: Gut | July 2026

Introduction: Altered gut motility is increasingly recognized as a contributor to metabolic dysfunction through the gut–brain axis. Enterosynes are gut-derived bioactive molecules that regulate intestinal motility and influence...

17

Diet–Microbiome Synergy Enhances Immunotherapy Response in Obesity: Nature | July 2026

Introduction: The gut microbiome and obesity are both known to influence cancer immunotherapy outcomes, yet the interaction between diet, obesity, and the microbiome has remained unclear. This landmark...

18

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial...

19

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable....

20

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a...

Previous
12314
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer